Viatris Inc. Viatris Inc.

Viatris Inc.

VTRS

Xếp hạng trong cổ phiếu #1107
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its... Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Giá cổ phiếu
$18.25
Vốn hóa thị trường
$20.96B
Thay đổi (1 ngày)
-2.20%
Thay đổi (1 năm)
79.40%
Quốc gia
US
Giao dịch Viatris Inc. (VTRS)

Danh mục

Healthcare
Lịch sử cổ tức của Viatris Inc. (VTRS)
Viatris Inc. (mã cổ phiếu: VTRS) đã thực hiện tổng cộng 95 lần chi trả cổ tức.
Tổng tất cả cổ tức (đã điều chỉnh theo chia tách cổ phiếu): $3.84
Tỷ suất cổ tức (TTM): 0.0275
Các khoản chi trả cổ tức của Viatris Inc. (VTRS) từ 1986 đến 2026
Các khoản chi trả cổ tức hàng năm
Năm Cổ tức (đã điều chỉnh chia tách cổ phiếu) Thay đổi
2026 (TTM) $0.12 -75.00%
2025 $0.48 0.00%
2024 $0.48 0.00%
2023 $0.48 0.00%
2022 $0.48 45.45%
2021 $0.33 175.00%
2007 $0.12 -50.00%
2006 $0.24 14.29%
2005 $0.21 75.00%
2004 $0.12 24.22%
2003 $0.0966 27.78%
2002 $0.0756 6.18%
2001 $0.0712 0.00%
2000 $0.0712 0.00%
1999 $0.0712 0.00%
1998 $0.0712 0.00%
1997 $0.0712 0.00%
1996 $0.0712 9.20%
1995 $0.0652 15.60%
1994 $0.0564 35.58%
1993 $0.0416 27.61%
1992 $0.0326 10.14%
1991 $0.0296 33.33%
1990 $0.0222 50.00%
1989 $0.0148 33.33%
1988 $0.0111 -25.00%
1987 $0.0148 100.00%
1986 $0.0074 0.00%
Danh sách tất cả các khoản chi trả cổ tức
Năm Cổ tức Thay đổi
2026 (TTM) $0.12 -75.00%
2025 $0.48 0.00%
2024 $0.48 0.00%
2023 $0.48 0.00%
2022 $0.48 45.45%
2021 $0.33 175.00%
2007 $0.12 -50.00%
2006 $0.24 14.29%
2005 $0.21 75.00%
2004 $0.12 -7.62%
2003 $0.1299 -23.59%
2002 $0.17 6.25%
2001 $0.16 0.00%
2000 $0.16 0.00%
1999 $0.16 0.00%
1998 $0.16 0.00%
1997 $0.16 0.00%
1996 $0.16 -11.11%
1995 $0.18 -5.26%
1994 $0.19 35.71%
1993 $0.14 -12.50%
1992 $0.16 -20.00%
1991 $0.2 33.33%
1990 $0.15 50.00%
1989 $0.1 33.33%
1988 $0.075 -25.00%
1987 $0.1 100.00%
1986 $0.05 0.00%
Cổ tức của các công ty tương tự hoặc đối thủ